IGF-1 LR3: What the Evidence Actually Shows

IGF-1 LR3 shows up constantly in bodybuilding and research-chemical marketing as a "more potent" version of insulin-like growth factor 1 — sold by the vial, dosed by the microgram, framed as a muscle-building peptide in the same breath as CJC-1295 or ipamorelin. Reading its own 1992 discovery paper end to end tells a different story about what this molecule actually is and what it was actually built for.

It was never designed to be a drug

"Long [Arg3]-IGF-I" — the molecule market listings shorten to "IGF-1 LR3" — was engineered by a CSIRO/University of Adelaide team who fused the first 11 amino acids of porcine growth hormone onto human IGF-1, with glutamic acid at position 3 swapped for arginine. The paper's own description of why: these analogues are "very useful reagents in the investigation of IGF-I action"¹. That is a laboratory-tool framing, not a therapeutic one, and it matters for everything that follows. The N-terminal extension and the Arg3 substitution both reduce the molecule's affinity for IGF-binding proteins (IGFBPs) — the proteins that normally sequester most circulating IGF-1 and buffer its activity. Strip that buffering away in a petri dish and you get a cleaner read on pure IGF-1-receptor signaling, which is exactly what the original researchers wanted. Every biological-activity result in that founding paper comes from rat L6 myoblasts, H35 hepatoma cells, and chicken embryo fibroblasts — cell culture, not a living animal, let alone a person¹.

Three decades later, still nobody's tested it in humans

A live PubMed search restricted to "long R3 IGF-1," "LR3-IGF-1," and "LR3 IGF-I" returns 39 results, read in full for this article. None of them is a human study. What the literature actually contains is fetal and neonatal livestock physiology — IGF-1 LR3 infused into fetal sheep to study organ growth, injected into beef heifers to study protein metabolism, fed to artificially-reared neonatal pigs to study growth rates²³ — plus industrial bioprocessing work using it as a fusion tag for recombinant protein production in yeast⁴. The most recent, and most clinically-adjacent, study located is a 2025 paper testing intranasal LR3-IGF-1 in a mouse model of Alzheimer's disease: it produced real amyloid plaque remodeling in the cerebral cortex, but the same study reports it "fails to preserve cognitive function" in the mice⁵ — a negative result on the one outcome that mattered, in the one recent study that comes closest to a real disease model. A 2026 peer-reviewed review of performance-enhancing peptides modulating the GH-IGF-1 axis, independently corroborating this article's own PubMed search rather than being the source of it, places IGF-1 LR3 in its lowest evidence tier — the category reserved for compounds with "no controlled clinical studies... in humans," alongside CJC-1295 without its DAC modification and PEG-MGF⁶.

What that means for the dosing and safety claims sold alongside it

Because no human study has ever administered IGF-1 LR3 to a person, at any dose, by any route, there is no human data on its half-life, its effective dose, its hypoglycemia risk, or any other safety outcome — full stop. This matters more for IGF-1 LR3 specifically than it would for an inert compound, because the entire design rationale of the molecule is reduced IGFBP binding: less of the body's own buffering system standing between the dose and the receptor. What that implies mechanistically — a higher fraction of unbound, bioactive IGF-1 activity per microgram than the body's own IGF-1 normally reaches — is a reasonable inference from the 1992 paper's own stated purpose, not a documented human finding. This article states it as exactly that: an inference from mechanism, not a measured outcome, and not something any dosing figure sold alongside this compound is backed by. Any specific microgram amount you see attached to "IGF-1 LR3" online is marketing copy, not a studied human dose — there isn't one to cite.

The regulatory picture: not even on FDA's radar

Semax, Kisspeptin, and AOD-9604 — the other three previously-uncovered compounds in this same research batch — have each been formally nominated to FDA for compounding-bulk-substance review at some point. IGF-1 LR3 has not. FDA's current 503A Bulks List, updated May 14, 2026 and fetched fresh for this article, contains no IGF-1 LR3 naming variant in any of its three categories⁷. FDA's companion page listing substances with documented significant safety concerns — which also separately tracks nominations that were later withdrawn — likewise has no match for IGF-1 LR3 under any naming variant, in either its active list or its historical section⁸. DailyMed, the National Library of Medicine's archive of FDA-approved drug labeling, returns zero results for "IGF-1 LR3," confirming no approved product exists under any form⁹. And openFDA's FAERS adverse-event database returns zero reports — the only one of this five-compound batch with a fully null result across every naming variant queried¹⁰. Read that null result honestly in both directions: it is not evidence of safety, because a compound nobody has ever formally studied or reported on generates no reports by definition, not because none exist to report.

What this means if you're considering it

IGF-1 LR3 is not a diluted or off-brand version of a studied drug — it is a laboratory reagent, built in 1992 to answer a specific cell-biology question about IGFBP binding, that the research-chemical market later re-marketed as a muscle-building peptide with no clinical development of any kind in between. None of the 31 providers this site's own reviews cover sell it as a primary, boarded product — this site's own identity-layer research (the same data behind its three provider boards) confirms IGF-1 LR3 is not tagged to any reviewed seller. There is no dedicated evidence base to weigh a benefit against, because the human evidence base does not exist: not thin, not mixed, not preliminary — absent. If you're comparing it against other growth-hormone-axis compounds this site does cover, our CJC-1295 and Ipamorelin evidence review at least has real (if narrow) human trial data behind each of its two compounds; our AOD-9604 evidence review covers a different GH-derived fragment that, unlike IGF-1 LR3, was actually tested in six placebo-controlled human safety trials before its efficacy program was shut down. IGF-1 LR3 has neither a clinical track record nor a failed one — it has never reached a person in a study at all.